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by Elsevier B.V. This is an open accesAbstract Background and objectives: To evaluate the frequency of antiphospholipid anti-
bodies (APLa) among patients with childhood lupus nephritis (cLN) and to assess their impact
on long-term renal outcomes.
Design and setting: This is an observational hospital based study.
Patients and methods: Patients with cLN diagnosed by renal biopsy seen between January 2002
and June 2014 were included. APLa positivity was defined if detection was positive on 2 occa-
sions 6e12 weeks apart during their follow up. Demographic features, age at disease onset,
disease duration, follow-up duration and clinical and laboratory variables at the time of renal
biopsy were collected. The renal biopsy was reviewed for the nephritis class, microthrombi,
activity and chronicity indices. Renal outcome measures included the serum creatinine levels,
protein/creatinine ratio and end stage renal disease (ESRD).
Results: Fifty-nine, (49 female) patients with a mean age of 19.8 years and mean disease dura-
tion of 6.8 years were involved. APLa were detected in 46 (78%) patients. Twenty-two patients
had class IV nephritis, which was more prevalent in APLa positive patients. The frequencies of
class III and V nephritis was similar in 10 patients in each class (7 patients in each class with
APLa). The presence of APLa did not correlate with nephritis activity or the chronicity indices.
Microthrombosis was found in 10 patients, and 8 of them had APLa. Patients with APLa had a
higher frequency of elevated serum creatinine and hypertension, 9 developed ESRD, and 7 had
APLa. There was no statistically significant association between the presence of APLa and the
accrual damage index and clinical manifestations. Furthermore, there was no association be-
tween APLa and other autoantibodies.of Pediatrics, MBC e 58, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh
761; fax: þ966 1 4427784.
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148 S.M. Al-Mayouf et al.Conclusion: The frequency of APLa in cLN was high. While the association is not statistically
significant, APLa positive patients tend to develop renal microthrombi and are probably at
higher risk of ESRD.
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Systemic lupus erythematosus (SLE) is a multi-system
autoimmune disease, and while it is predominantly a dis-
ease of young women, childhood SLE represents approxi-
mately 20% of all SLE cases [1,2]. The onset and clinical
manifestations of childhood SLE are often aggressive, with
widespread organ involvement [3,4]. Childhood lupus
nephritis (cLN) occurs in almost 30e60% of cases, and it
may present with proteinuria, haematuria, hypertension,
and occasionally, renal impairment. Furthermore, the
renal outcomes reported by several studies suggest that it
is more frequent and aggressive compared to the adult
disease [5,6].
In general, cLN remains indicative of poor outcomes,
which is especially true of diffuse proliferative glomerulo-
nephritis, the most severe type, which is most frequently
associated with the development of end stage renal disease
(ESRD) or death [7,8].
Like other autoimmune diseases, the aetiology of SLE
remains unknown. However, the primary pathology results
from massive autoantibody production followed by immune
complex deposition. Among these autoantibodies, anti-
phospholipid antibodies (APLa), which are a heterogeneous
group of pathogenic autoantibodies, are directed against
negatively phospholipid-binding proteins. APLa, including
lupus anticoagulant (LAC), anticardiolipin antibody (aCL),
and anti-b2 glycoprotein I (b2GPI) antibody, are frequently
observed in SLE patients and are associated with the
increased risk and frequency of thrombosis at different
sites [9,10]. A variety of renal manifestations, including
intra-glomerular capillary thrombosis and nephropathy,
have been reported in APLa positive SLE patients. However,
the true significance of APLa on the progression of lupus
nephritis is still controversial [11e14].
In this study, we evaluated the frequency of APLa among
patients with cLN and assessed the impact of APLa on long-
term renal outcomes. To the best of our knowledge, there
is no available published data from the Middle East about
the impact of APLa in cLN.
2. Patients and methods
This observational study was composed of all of the pa-
tients with childhood onset SLE with biopsy-proven
nephritis who were followed at the lupus clinic at the
King Faisal Specialist Hospital and Research Centre
(KFSHRC)-Riyadh, Saudi Arabia, between January 2002 and
June 2014. All included patients fulfilled the definition of
SLE using the Systemic Lupus International Collaborating
Clinic classification criteria for systemic lupus erythema-
tosus [15].The patients were classified APLa positive if they had at
least one of APLa (aCL IgG >15 GPL/mL, IgM >7 MPL/mL,
b2GPI IgA >3 SA U/mL, b2GPI IgG >10 SG U/mL, or b2GPI
IgM >12 SM U/mL) detected on 2 occasions 6e12 weeks
apart during their follow up. The measurement of APLa was
performed by Automated ELISA (ETI -Max 3000) using
commercial kits (Diasorin kit, Saluggia, Italy).
A renal histopathologist reviewed all of the renal bi-
opsies independently without knowledge of the APLa
status. The histopathology assessment included a classifi-
cation of the nephritis class according to the lupus nephritis
classification system of the International Society of
Nephrology/Renal Pathology Society (ISN/RPS) and the ac-
tivity and chronicity of nephritis and the presence of
microthrombosis [16].
Demographic data, age at disease onset, disease dura-
tion, and follow up duration data were extracted from pa-
tients’ medical records. Clinical and laboratory data,
including serum urea and creatinine, urinalysis, protein/
creatinine ratio, antinuclear antibody (ANA), anti-double
stranded DNA antibody (ds-DNA), and serum complement
(C3, C4) levels,were collected at the time of the renal biopsy.
The renal outcomes were assessed according to the
serum creatinine level, the protein/creatinine ratio, and
the ESRD. The previous items are indicated in the pediatric
adaptation of the Systemic Lupus International Collabo-
rating Clinics/American College of Rheumatology Damage
Index score (pSDI) [7].
All of the collected data were analyzed confidentially,
and no identifying data were needed. All of the clinical and
laboratory assessments were a result of routine medical
care, and informed consent was obtained at the time of the
renal biopsy. The proposal was approved by the Research
Affairs Council at KFSHRC.
3. Statistical methods
To determine the impact of APLa on nephritis, we compared
APLa positive cLN patients with APLa negative cLN patients.
SAS 9.2 (SAS Institute Inc., Cary, NC, USA) software was used
for the statistical analyses. The variables were compared
using 2-sample t-tests, chi-square tests and Fisher’s exact
tests. The results are expressed as the mean  standard
deviation (SD) for continuous variables and as percentages
for categorical variables. Regression analysis was carried out
to examine the impact of APLa on long-term renal outcomes.
P values < .05 were considered significant.
4. Results
A total of 59 (49 females) patients with biopsy-proven
nephritis were included, with a mean age of 19.8 years
Table 2 A comparison of nephritis classes, renal indices
and renal outcomes between APLa positive and negative
patients.a
APLa positive APLa negative
Number of patients 46 13
Age (years) 19.1 (3.6) 19.4 (4.1)
Gender (F:M) 38:8 11:2
Disease duration (years) 6.6 (3.2) 7.7 (4.9)
Follow-up duration (years) 6 (3.2) 7 (4.9)
pSDI 1.54 (1.82) 1.36 (1.96)
Creatinine/protein ratio 0.31 (0.48) 0.13 (0.15)
Serum Creatinine mmol/L 102 (93.9) 70.9 (50.4)
Lupus nephritis class
II 6 1
III 7 3
IV 19 3
V 7 3
VI 1 0
IV þ V 4 1
III þ V 4 0
Activity 4.9 (3.7) 5.4 (4.3)
Chronicity 2.6 (2.1) 2.8 (2.0)
Microthrombi 8 2
ESRD 7 2
APLa Z antiphospholipid antibodies, pSDI Z pediatric adapta-
tion of the Systemic Lupus International Collaborating Clinics/
American College of Rheumatology Damage Index score,
ESRD Z End stage renal disease.
a The differences are not statistically significant.
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mean follow-up duration of 6.2 years (3.6). The distribu-
tion of the ISN/RPS classification was follows: 22 patients
had class IV nephritis, while class III and V nephritis had
similar frequencies, with 10 patients in each class; 7 pa-
tients had class II nephritis; 5 patients had mixed class IV
and V; 4 patients had mixed class III and V; and one patient
had class VI nephritis. During the follow-up period, in
addition to nephritis, haematological, mucocutaneous,
neurological and cardiovascular involvements were the
most frequent clinical manifestations. Twenty-one patients
had haematological manifestations in the form of direct-
coombs test related haemolytic anaemia, leukopenia, and
thrombocytopenia, although most of these findings were
transient. Twelve patients had mucocutaneous manifesta-
tions, including oral ulcerations and facial rashes, 2 had
discoid rashes, and none had livedo reticularis. Nine pa-
tients had neurological manifestations, 4 of whom devel-
oped lupus cerebritis complicated by cerebral ischaemia, as
shown by brain magnetic resonance imaging and angiog-
raphy; 4 patients had seizure disorders; and one patient
had psychosis. Six patients had cardiovascular involvement:
4 patients developed pericardial effusion; one had de-
pressed myocardial contractility, as manifested by a de-
creased ejection faction; and 2 patients were complicated
by mitral valve regurgitations, none of whom had valve
vegetation.
All patients received corticosteroids, hydroxych-
loroquine and immunosuppressive treatment. Table 1
presents the frequency of the use of immunosuppressive
drugs. The main indication of cyclophosphamide therapy
was renal involvement, mainly class IV, followed by lupus
cerebritis. However, rituximab was used mainly for
nephritis class IV or class V.
Overall, 35 (59.3%) patients had disease damage; the
mean accrual damage was 1.52 (1.8). The damage was
mostly in growth followed by renal then neuropsychiatric
domains.
APLa were detected in 46 (78%) patients; anti b2GPI IgG,
b2GPI IgA, and b2GPI IgM antibodies were detected in
60.9%, 50% and 32.6%, respectively; and aCL IgM and aCL
IgG antibodies were detected in 39.1% and 32.6% of the 46
APLa positive patients, respectively.
Table 2 presents the differences between APLa positive
patients and APLa negative patients. There were no sig-
nificant differences in patient age, disease duration or
follow-up duration. Among the 22 patients with class IV
nephritis, 19 were APLa positive. The frequencies of class III
and V nephritis were similar, with 10 patients in each class
(7 APLa positive patients in each class). The activity and
chronicity indices were comparable. However,Table 1 A summary of the immunosuppressive drugs in 59
patients with cLN.
Drug Frequency
Cyclophosphamide 39 (66.1%)
Mycophenolate mofetil 27 (45.8%)
Rituximab 15 (25.4%)
Azathioprine 14 (23.7%)microthrombosis was more frequent in APLa positive
compared to APLa negative patients (8 patients versus 2
patients). Two out of the 8 APLa positive patients had
microthrombi in the small arterioles, while the other pa-
tients had intra-glomerular microthrombosis. All patients
with microthrombosis had proliferative glomerulonephritis.
Additionally, APLa positive patients had higher serum
creatinine levels and proteinuria. Furthermore, established
renal damage was observed at the last follow-up visit in 7
APLa positive patients compared to 2 APLa negative pa-
tients. These differences did not reach statistical signifi-
cance (P values > .05). There was no statistically significant
association between the presence of APLa and accrual
damage and clinical manifestations, including hypertension
and arterial thrombosis. Additionally, there was no associ-
ation between APLa and other autoantibodies and com-
plement levels.
5. Discussion
SLE is an autoimmune disease that is characterized by
multiple organ involvement and a frequently relapsing
disease course with an increased risk of comorbidities,
including renal impairment. The presence of APLa in
childhood SLE and even transient or intermittent APLa,
could be a risk factor for a poor prognosis [17]. The actual
impact of APLa in the pathogenesis and progression of renal
lesions in SLE patients requires further research, particu-
larly in children, and data regarding the correlations
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comes in cLN are scarce.
In the current study, we demonstrated that 78% of pa-
tients with cLN were APLa positive, which is comparable to
the findings previously reported previously in childhood SLE
[18]. All enrolled patients had nephritis with a long follow
up period. Most patients had class IV nephritis, which was
more prevalent in APLa positive patients. However, this
difference was not statistically significant. In previous
studies, glomerular changes and nephritis classes were not
related to the presence of APLa [14,19,20]. Similarly, we
did not find an association between the presence of APLa
and different nephritis classes. Our results are comparable
with the previous findings that APLa positivity does not
correlate with renal histological activity and chronicity
indices [14,19,21]. APLa are often observed in SLE patients
and increase the risk of thrombosis at different sites and
probably increase thrombotic complication in lupus
nephritis. Previous reports demonstrated that the presence
of APLa is a strong predicator for intra-glomerular capillary
thrombosis. Furthermore, patients with intra-glomerular
microthrombosis had more renal tissue injuries and poorer
renal outcomes compared to patients without intra-
glomerular microthrombosis [22,23]. On the other hand,
another study found that the detection rate of APLa was
higher in patients with intra-glomerular microthrombosis,
which indicates the pathogenic significance of APLa in lupus
nephritis [24]. In this study, we did not find a significant
correlation between the presence of APLa and micro-
thrombosis. Nonetheless, 10 patients had renal micro-
thrombosis, and two of the eight APLa positive patients had
microthrombi in the arterioles and severe disease man-
ifested by refractory hypertension, lupus cerebritis and
ESRD. However, it is still not known whether the presence
of APLa accelerates renal impairment in SLE patients,
although a few studies have suggested that APLa is a risk
factor for increased serum creatinine levels and the
elevated prevalence of hypertension and probably con-
tributes to poor long-term renal outcomes [13]. Our findings
show that patients with APLa had a higher frequency of
elevated serum creatinine levels and hypertension; nine
developed ESRD, and seven had APLa. The association of
APLa with different clinical and laboratory findings,
particularly in patients with life-threatening disease, is still
debatable, although APLa were significantly associated
with anti-ds-DNA antibody levels and haemolytic anaemia
[18,25]. In our study, however, no statistically significant
association was observed between the presence of APLa
and the accrual damage index or clinical manifestations,
such as hypertension and arterial thrombosis or other au-
toantibodies and complement levels.
We did not examine APLa level fluctuations during the
study follow-up period or distinguish between different
APLa subtypes. Additionally, we did not attempt to eval-
uate the efficiency of antiplatelet or anticoagulant treat-
ment in patients with intra-glomerular microthrombosis
because of the study limitations and design.
In summary, this is the first study from the Middle East
regarding the relationship between the presence of APLa
and renal outcomes in childhood SLE. Our findings suggest a
probable prognostic consequence of APLa on the long-term
outcomes of cLN. We realize that the studied sample issmall; therefore, these results should be interpreted with
caution. Further prospective investigation into the role of
APLa in the long-term renal outcomes of childhood SLE is
warranted.Conflict of interest
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